Protocol Ledger

NCT06920004 · Phase III · RECRUITING

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Interventional Phase III clinical trial protocol NCT06920004 sponsored by argenx in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-22 Enrollment: 218 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06920004
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)218 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06920004
Protocol FieldVerified Registry Value
NCT IdentifierNCT06920004
Consolidated Lead Sponsorargenx
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment218 participants (ESTIMATED)
Registered Start Date2025-08-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06920004
Hospital Research SiteLocationSite Profile
MedStar Washington Hospital CenterWashington D.C, DCOpen Hospital Dossier ->
University of South FloridaTampa, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI